Short Interest in Opus Genetics, Inc. (NASDAQ:IRD) Increases By 31.5%

02 Feb 2026, 17:08 by Renee Jackson · The Cerbat Gem

Opus Genetics, Inc. (NASDAQ:IRD – Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 957,806 shares, a growth of 31.5% from the December 31st total of 728,362 shares. Based on an average daily volume of 463,062 shares, the short-interest ratio is presently 2.1 days. Currently, 1.5% of the company’s stock are sold short. Currently, 1.5% of the company’s stock are sold short. Based on an average daily volume of 463,062 shares, the short-interest ratio is presently 2.1 days.

Insider Transactions at Opus Genetics

In other news, Director Fighting Blindness Foundation sold 4,000,000 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $2.15, for a total transaction of $8,600,000.00. Following the sale, the director owned 5,492,171 shares in the company, valued at approximately $11,808,167.65. The trade was a 42.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cam Gallagher purchased 83,000 shares of the business’s stock in a transaction on Monday, December 29th. The shares were bought at an average price of $1.97 per share, for a total transaction of $163,510.00. Following the purchase, the director directly owned 83,000 shares in the company, valued at $163,510. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 6.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Opus Genetics

Several hedge funds have recently modified their holdings of the company. Comerica Bank acquired a new stake in Opus Genetics during the first quarter worth approximately $29,000. Raymond James Financial Inc. boosted its holdings in Opus Genetics by 95.6% in the third quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after acquiring an additional 11,000 shares during the last quarter. Two Sigma Investments LP grew its position in Opus Genetics by 169.6% during the third quarter. Two Sigma Investments LP now owns 108,338 shares of the company’s stock valued at $179,000 after acquiring an additional 68,148 shares during the period. Citadel Advisors LLC increased its stake in Opus Genetics by 496.9% during the third quarter. Citadel Advisors LLC now owns 113,416 shares of the company’s stock worth $187,000 after acquiring an additional 94,416 shares during the last quarter. Finally, Creative Planning purchased a new position in shares of Opus Genetics in the 3rd quarter worth about $212,000. 14.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on IRD. B. Riley started coverage on Opus Genetics in a report on Wednesday, December 10th. They issued a “buy” rating and a $9.00 price objective for the company. Wall Street Zen upgraded shares of Opus Genetics from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Brookline Capital Management raised shares of Opus Genetics to a “strong-buy” rating in a research note on Monday, December 1st. Piper Sandler started coverage on Opus Genetics in a report on Tuesday, November 25th. They issued an “overweight” rating and a $7.00 price target for the company. Finally, Wedbush started coverage on shares of Opus Genetics in a research note on Wednesday, October 29th. They set an “outperform” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.75.

Get Our Latest Stock Report on Opus Genetics

Opus Genetics Stock Performance

IRD traded up $0.01 during trading on Monday, hitting $2.32. 493,762 shares of the stock were exchanged, compared to its average volume of 691,817. The firm has a market capitalization of $160.00 million, a P/E ratio of -1.23 and a beta of 0.41. The stock has a fifty day moving average price of $2.18 and a two-hundred day moving average price of $1.78. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.18. Opus Genetics has a 1-year low of $0.65 and a 1-year high of $3.05.

Opus Genetics (NASDAQ:IRD – Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. The company had revenue of $3.08 million for the quarter, compared to the consensus estimate of $3.07 million. Opus Genetics had a negative return on equity of 697.94% and a negative net margin of 466.09%. As a group, sell-side analysts predict that Opus Genetics will post -1.22 earnings per share for the current year.

Opus Genetics Company Profile

(Get Free Report)